Homocysteine and endothelial function in human studies

Seminars in Vascular Medicine

Volumn 5, Issue 2, 2005, Pages 172-182

  Moat, Stuart J ^a   McDowell, Ian F W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Endothelium; Flow mediated dilation; Nitric oxide; Tetrahydrobiopterin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BETAINE; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; GLYCERYL TRINITRATE; HOMOCYSTEINE; METHIONINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PYRIDOXINE; TETRAHYDROBIOPTERIN;

BIOAVAILABILITY; CARDIOVASCULAR DISEASE; ENDOTHELIUM; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASODILATATION;

BLOOD FLOW VELOCITY; ENDOTHELIUM, VASCULAR; FOLIC ACID; HEMATINICS; HOMOCYSTEINE; HOMOCYSTINURIA; HUMANS; HYPERHOMOCYSTEINEMIA; VASCULAR DISEASES; VASODILATION;

EID: 21744440729     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-872402     Document Type: Review

References (66)

1. Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res 1996;33:181-194
2. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999;31:51-60
3. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265
4. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-1906
5. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-954
6. Gokce N, Keaney JF Jr, Hunter LM. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003;41:1769-1775
7. Halcox JP, Schenke WH, Zalos G. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-658
8. Esper RJ, Machado R, Vilarino J, et al. Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined. Am Heart J 2000;140:684-689
9. Finta KM, Fischer MJ, Lee L, Gordon D, Pitt B, Webb RC. Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis 1993;100:149-156
10. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-597
11. Goodfellow J, Bellamy MF, Ramsey MW, Jones CJ, Lewis MJ. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 2000;35:265-270
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
13. Effect of ramipril on martality and morvidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators. Lancet 1993;342:821-828
14. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717
15. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto miocardico. Lancet 1999;354:447-455
16. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128
17. Celermajer DS, Sorensen K, Ryalls M, et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993;22:854-8S8
18. Pullin CH, Bonham JR, McDowell IF, et al. Vitamin C therapy ameliorates vascular endothelial dysfunction in treated patients with homocystinuria. J Inherit Metab Dis 2002;25:107-118
19. Yap S, Boers GH, Wilcken B, et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 2001;21:2080-2085
20. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997;95:1119-1121
21. Woo KS, Chook P, Lolin YI, et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997;6:2542-2544
22. Bellamy MF. Homocysteine and endothelial function. MD thesis, University of London; 2000
23. Woodman RJ, Celermajer DE, Thompson PL, Hung J. Folic acid does not improve endothelial function in healthy hyperhomocysteinaemic subjects. Clin Sci 2004;106:353-358
24. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C → T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288:2023-2031
25. Puffin CH, Ashfield-Watt PA, Burr ML, et al. Optimization of dietary folate or low-dose folk acid supplements lower homocysteine but do not enhance endothelial function in healthy adults, irrespective of the methylenetetrahydrofolate reductase (C677T) genotype. J Am Coll Cardiol 2001;38:1799-1805
26. Butler R, Morris AD, Struthers AD. The T allele of the C (677)T 5,10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism may protect endothelial function in young, normal subjects. Arterioscler Thromb Vasc Biol 2002;22:193-194
27. Bellamy MF, McDowell IF, Ramsey MW, et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998;98:1848-1852
28. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation 1999;99:1156-1160
29. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction by acute hyperhomocyst (e)inaemia: restoration by folic acid. Clin Sci 1999;96:235-239
30. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999;100:1161-1168
31. Chao CL, Kuo TL, Lee YT. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation 2000;101:485-490
32. Nappo F, De Rosa N, Marfella R, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999;281:2113-2118
33. Hanratty CG, McAuley DF, McGurk C, Young IS, Johnston GD. Homocysteine and endothelial vascular function. Lancet 1998;351:1288-1289
34. Chambers JC, Ueland PM, Wright M, Dore CJ, Refsum H, Kooner JS. Investigation of relationship between reduced, oxidized, and protein-bound homocysteine and vascular endothelial function in healthy human subjects. Circ Res 2001;89:187-192
35. Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci 2001;100:161-167
36. Stuhlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 2003;108:933-938
37. Wanby P, Brattstrom L, Brudin L, Hultberg B, Teerlink T. Asymmetric dimethylarginine and total homocysteine in plasma after oral methionine loading. Scand J Clin Lab Invest 2003;63:347-353
38. Doshi SN, McDowell IF, Goodfellow J, et al. Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine and endothelial function in healthy human subjects during experimental hyper and hypohomocysteinaemia. Metabolism 2005;54:351-360
39. Hanratty C, McGrath L, McAuley D, Young I, Johnston D. The effect on endothelial function of vitamin C during methionine induced hyperhomocysteinaemia. BMC Cardiovasc Disord 2001;1:1 Epub
40. Chao CL, Chien KL, Lee YT. Effect of short-term vitamin (folic acid, vitamins B6 and B12) administration on endothelial dysfunction induced by post-methionine load hyperhomocysteinemia. Am J Cardiol 1999;84:1359-1361
41. Zheng H, Dimayuga C, Hudailhed A, Katz S. Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects. Aterioscler Thromb Vasc Biol 2002;22:E15-E18
42. Moat SJ, Lang D, McDowell IFW, et al. Folate, endothelial fonction and cardiovascular disease. Invited review. J Nutr Biochem 2004;15:64-79
43. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Newcombe RG, Lewis MJ. Oral folate enhances endothelial fonction in hyperhomocysteinaemic subjects. Eur J Clin Invest 1999;29:659-662
44. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial fonction in adults with hyperhomocystinemia. J Am Coll Cardiol 1999;34:2002-2006
45. Gori T, Burstein JM, Ahmed S, et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 2001;104:1119-1123
46. Wilmink HW, Stroes ES, Erkelens WD, et al. Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol 2000;20:185-188
47. van Guldener C, Janssen MJ, Lambert J, et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998;13:106-112
48. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Does folic acid decrease plasma homocysteine and improve endothelial fonction in patients with predialysis renal failure? Circulation 2000;102:871-875
49. Doshi SN, McDowell IF, Moat SJ, et al. Folate improves endothelial fonction in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol 2001;21:1196-1202
50. Doshi SN, McDowell IF, Moat SJ, et al. Folic acid improves endothelial fonction in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002;105:22-26
51. Title LM, Cummings PM, Giddens K, Genest JJ Jr, Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000;36:758-765
52. Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular endothelial fonction after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000;102:2479-2483
53. Madhavan A, Moat SJ, McDowell IFW, Lewis MJ, Goodfellow J, Lang D. High- but not low-dose folic acid improves endothelial fonction in coronary artery disease. J Am Coll Cardiol 2004;43(517A):159-1186
54. Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-methyltetrahydrofolate, the active form of folic acid restores endothelial dysfunction in familial hypercholesterolaemia. Circulation 1998;97:237-241
55. Nakano E, Higgins JA, Powers HJ. Folate protects against oxidative modification of human LDL. Br J Nutr 2001;86:637-639
56. Vasquez-Vivar J, Martasek P, Whitsett J, Joseph J, Kalyanaraman B. The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. Biochem J 2002;362:733-739
57. Stroes E, Kastelein J, Cosentino F, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997;99:41-46
58. Maier W, Cosentino F, Lutolf RB, et al. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol 2000;35:173-178
59. Stroes ES, van Faassen EE, Yo M, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000;86:1129-1134
60. Hyndman ME, Verma S, Rosenfeld RJ, Anderson TJ, Parsons HG. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol 2002;282:H2167-H2172
61. Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner E. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 2001;276:40-47
62. Baker F, Picton D, Blackwood S, et al. Blinded comparison of folic acid and placebo in patients with ischaemic heart disease: an outcome trial. Circulation 2002;106(Supplement 1):741
63. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Juema JW, van Veldhuisen DJ. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 2003;41:2105-2113
64. Toole J, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischaemic stroke to prevent recurrent stroke, myocardial infarction, and death. The vitamin Intervention for Stroke Prevention (VISP) Randomised Controlled Study. JAMA 2004;291:565-575
65. Lowering blood homcysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 1998;316:894-898
66. Doshi SN, Moat SJ, McDowell IFW, Lewis MJ, Goodfellow J. Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us? Atherosclerosis 2002;165:1-3